Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · IEX Real-Time Price · USD
43.98
+0.24 (0.55%)
At close: May 1, 2024, 4:00 PM
44.75
+0.77 (1.75%)
After-hours: May 1, 2024, 7:21 PM EDT
Legend Biotech Revenue
In the year 2023, Legend Biotech had annual revenue of $285.14M with 143.70% growth. Revenue in the quarter ending December 31, 2023 was $79.46M with 187.57% year-over-year growth.
Revenue (ttm)
$285.14M
Revenue Growth
+143.70%
P/S Ratio
28.06
Revenue / Employee
$156,157
Employees
1,826
Market Cap
8.00B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 285.14M | 168.14M | 143.70% |
| Dec 31, 2022 | 117.01M | 48.18M | 70.00% |
| Dec 31, 2021 | 68.83M | -6.17M | -8.23% |
| Dec 31, 2020 | 75.00M | 15.02M | 25.04% |
| Dec 31, 2019 | 59.98M | 10.85M | 22.08% |
| Dec 31, 2018 | 49.13M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Encompass Health | 4.80B |
| Bio-Rad Laboratories | 2.67B |
| Chemed | 2.29B |
| Stevanato Group | 1.21B |
| Penumbra | 1.06B |
| Ascendis Pharma | 296.35M |
| Roivant Sciences | 123.24M |
LEGN News
- 9 days ago - CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma - Business Wire
- 20 days ago - Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results - Business Wire
- 26 days ago - Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma - Business Wire
- 6 weeks ago - Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report - Business Wire
- 6 weeks ago - CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma - Business Wire
- 7 weeks ago - Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights - Business Wire
- 2 months ago - Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy - Business Wire
- 2 months ago - Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results - Business Wire